Viibryd (Vilazodone) Dose Range
The recommended dose range for Viibryd is 20 mg to 40 mg orally once daily with food, starting at 10 mg daily for 7 days, then increasing to 20 mg daily, with optional titration to 40 mg after a minimum of 7 additional days. 1
Standard Dosing Protocol
The FDA-approved dosing schedule follows a specific titration:
- Week 1: Start 10 mg once daily with food
- Week 2 onward: Increase to 20 mg once daily with food
- Week 3+ (optional): May increase to 40 mg once daily with food after minimum 7 days at 20 mg
Food is essential - Viibryd must be taken with food for optimal bioavailability and effectiveness 1, 2. This is a critical point often missed in clinical practice.
Target Therapeutic Range
The therapeutic target is 20-40 mg daily 1. Both doses demonstrated statistically significant efficacy versus placebo in major depressive disorder, with improvements noted as early as week 1 3, 4. The 40 mg dose is generally considered the optimal therapeutic dose based on clinical trial data 2, 4.
Dose Adjustments for Drug Interactions
With Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin, voriconazole):
- Maximum dose: 20 mg once daily 1
- Resume original dose when inhibitor discontinued
With Strong CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin used >14 days):
- Consider increasing dose 2-fold, up to maximum 80 mg once daily over 1-2 weeks 1
- Taper back to original dose over 1-2 weeks when inducer discontinued
Discontinuation Tapering
When stopping Viibryd, gradual dose reduction is recommended 1:
- From 40 mg: Reduce to 20 mg for 4 days, then 10 mg for 3 days
- From 20 mg: Reduce to 10 mg for 7 days
Clinical Considerations
Tolerability differences: While a study comparing three dose-initiation strategies (10 mg, 20 mg, and 40 mg starting doses) found no meaningful efficacy differences, diarrhea was more frequently reported with the 40 mg initiation dose 5. This supports the FDA's gradual titration approach to minimize gastrointestinal side effects.
Common adverse effects at therapeutic doses include diarrhea (most common), nausea, vomiting, and insomnia 3, 2, 4. Most adverse events are mild-to-moderate and often self-limited, resolving within 4-5 days 6.
Critical safety warning: Unlike typical SSRIs, vilazodone can cause serotonin syndrome even in single-substance ingestions 7, 8. Children are particularly vulnerable, with major toxicity reported after ingestion of as little as 10 mg 7. This underscores the importance of proper storage and patient counseling.
MAOI interactions: Allow at least 14 days between discontinuing an MAOI and starting Viibryd, and vice versa 1.